A Phase I dose‐escalation study of two cycles carboplatin‐olaparib followed by olaparib monotherapy in patients with advanced cancer

Preclinical studies have shown synergistic effects when combining PARP1/2 inhibitors and platinum drugs in BRCA1/2 mutated cancer cell models. After a formulation change of olaparib from capsules to tablets, we initiated a dose finding study of olaparib tablets bidaily (BID) continuously with carbop...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Int J Cancer
Autors principals: Geenen, Jill J. J., Dackus, Gwen M. H. E., Schouten, Philip C., Pluim, Dick, Marchetti, Serena, Sonke, Gabe S., Jóźwiak, Katarzyna, Huitema, Alwin D. R., Beijnen, Jos H., Schellens, Jan H. M., Linn, Sabine C.
Format: Artigo
Idioma:Inglês
Publicat: John Wiley & Sons, Inc. 2021
Matèries:
Cancer Therapy and Prevention
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8248128/
https://ncbi.nlm.nih.gov/pubmed/33539540
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ijc.33498
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars